In this article, I’ll digest the human evidence available at the time of writing and look at:
- What we know about potential interactions between NMN, resveratrol and prescription medication
- Where the human evidence is reassuring
- Where the evidence is still limited
- Which commonly used medications may need more consideration
1. How can a supplement interact with medication?
When you take a medicine, your body has to absorb it, process it and eventually eliminate it.
An important part of this process involves a family of enzymes known as cytochrome P450 enzymes, usually shortened to CYP450.
Many prescription medications rely on these enzymes for their metabolism.
If a supplement inhibits one of these enzymes, a medicine may be broken down more slowly, potentially increasing the amount that remains in the bloodstream.
The reverse can also happen. Some medications need to be converted into an active form before they work properly. If that conversion is reduced, the medicine may potentially become less effective.
This is why supplement–medication interactions are not simply a question of whether something is “safe” or “unsafe.” The medication, metabolic pathway and dose of the supplement all matter.
2. What do we know about NMN and medication?
NMN, or nicotinamide mononucleotide, is a naturally occurring molecule that the body uses in the production of NAD+, an essential coenzyme involved in cellular energy metabolism and many other biological processes.
We now have several controlled human studies investigating oral NMN.
In one randomized, placebo-controlled trial, healthy adults received 250 mg of NMN daily for 12 weeks. NMN increased blood NAD+ concentrations, and researchers reported no abnormalities in the physiological or laboratory safety measures they monitored.¹
Another randomized trial involving 80 healthy middle-aged adults studied 300 mg, 600 mg and 900 mg daily for 60 days. NAD+ concentrations increased across the NMN groups, and researchers reported no safety concerns based on adverse events, laboratory tests and clinical measurements.²
A separate randomized trial tested a considerably higher dose of 1,250 mg daily for four weeks in healthy adults and also found NMN to be generally well tolerated during the study period.³
Does that mean NMN cannot interact with medication?
No.
This is where it is important to distinguish between reassuring safety data and dedicated drug-interaction research.
These NMN studies were not designed to systematically test NMN alongside commonly prescribed medications.¹⁻³
So, based on the human evidence available, there is not currently a recurring medication-interaction signal that would lead me to consider NMN inherently high risk for people taking medication.
But I would not describe NMN as proven to be “interaction-free” either.
The most accurate conclusion is that the available human safety data are reassuring, while dedicated medication-interaction data remain limited.
3. Resveratrol needs more consideration
Resveratrol is different because we do have human evidence showing that higher supplemental doses can affect enzymes involved in drug metabolism.
One of the most relevant studies involved 42 healthy adults who took 1,000 mg of resveratrol daily for four weeks.
Researchers used different substances to measure the activity of four CYP450 pathways and found that resveratrol inhibited CYP3A4, CYP2D6 and CYP2C9, while increasing the measured activity of CYP1A2.⁴
This matters because CYP3A4, CYP2D6 and CYP2C9 are involved in the metabolism of many commonly prescribed medications.
Importantly, this study does not tell us that everyone taking resveratrol with medication will experience an interaction.
It tells us that an interaction is biologically plausible, particularly at higher supplemental doses.
4. Losartan (Cozaar) gives us a useful real-world example
Losartan (Cozaar) is a common blood-pressure medication and was used as one of the probe drugs in the resveratrol study.
Losartan is converted into an active metabolite called E-3174, with CYP2C9 playing an important role in this conversion. Research in humans with reduced CYP2C9 activity has shown reduced formation of this active metabolite and, in one small study, a reduced blood-pressure response.⁵
After participants took 1,000 mg of resveratrol per day for four weeks, the resveratrol study found significant inhibition of the CYP2C9 pathway when Losartan was used as the probe drug.⁴
There is an important distinction here:
This was not a clinical trial showing that resveratrol stopped Losartan from controlling blood pressure.
Losartan was being used to measure CYP2C9 activity.
So this does not mean somebody taking Losartan cannot take resveratrol.
It simply means that, particularly at higher doses of resveratrol, there is a plausible mechanism through which Losartan metabolism could be altered.
5. Which other medications could potentially be affected?
Many common medications are processed through CYP450 pathways that may be influenced by resveratrol.⁴
Examples include:
- Amlodipine (Norvasc) — CYP3A4⁸
- Metoprolol (Lopressor / Toprol-XL) — CYP2D6⁹
- Atorvastatin (Lipitor) — CYP3A4¹⁰
- Warfarin (Coumadin / Jantoven) — CYP2C9¹¹
This does not mean resveratrol cannot be taken with these medications.
It simply means there is a potential for interaction because they share metabolic pathways that resveratrol has been shown to affect at higher doses.⁴
If you take one of these medications, discuss your resveratrol use with your physician, particularly if you are taking a higher dose.
6. Why the dose of resveratrol matters
This is an important part of interpreting the evidence.
The main human drug-interaction study used 1,000 mg of resveratrol per day.⁴
But there is evidence of biological activity at lower doses.
In a randomized, double-blind crossover study, healthy adults received either 250 mg or 500 mg of resveratrol. Both doses produced measurable changes in cerebral blood-flow variables, although cognitive performance itself did not improve.⁶
At much higher doses, tolerability becomes another consideration.
A separate human study gave participants 500 mg, 1,000 mg, 2,500 mg or 5,000 mg of resveratrol daily for 29 days. Gastrointestinal side effects became more apparent at the higher 2,500 mg and 5,000 mg doses.⁷
Why our formula contains 500 mg
Our formula contains 500 mg of resveratrol per daily serving.
We chose this dose deliberately.
It is a dose that has been studied in humans and shown biological activity, while being half the 1,000 mg/day dose used in the main human CYP450 interaction study and well below the multi-gram doses associated with more gastrointestinal side effects.⁴˒⁶˒⁷
That does not mean 500 mg has been proven incapable of interacting with medication. We do not have evidence establishing a precise dose below which medication interactions cannot occur.
Instead, it reflects a principle I use when considering supplement doses:
Use a meaningful dose supported by human research without unnecessarily escalating the dose when higher exposure may increase the potential for side effects or medication interactions.
More is not automatically better.
7. What should you do if you take prescription medication?
If you take medication and are considering NMN or resveratrol:
- Do not stop or change your prescription medication because you are taking a supplement.
- Tell your physician which supplements you are taking and at what dose.
- Be particularly careful if you take medications that require close monitoring, such as Warfarin (Coumadin / Jantoven).
- If you take medication for blood pressure or heart rate, continue whatever monitoring your physician has recommended.
- Do not assume that taking your medication and resveratrol at different times of day completely removes the possibility of an interaction.
The bottom line
NMN: The human studies available so far provide reassuring short-term safety data across a range of doses. However, dedicated studies looking specifically at interactions with prescription medication remain limited.¹⁻³
Resveratrol: There is stronger evidence for potential medication interactions because 1,000 mg/day has been shown in humans to alter several CYP450 pathways involved in drug metabolism.⁴
Dose matters: Our formula contains 500 mg of resveratrol — a dose with precedent in human research and half the amount used in the main human CYP450 interaction study. That does not make 500 mg interaction-free, but it is one reason we have not simply pursued increasingly high doses.⁴˒⁶˒⁷
For most people, taking medication does not automatically mean NMN or resveratrol must be avoided.
It means the medication, supplement dose and individual patient should be considered together.
If you take regular prescription medication, make sure your physician knows which supplements you are taking so they can decide whether any additional monitoring is appropriate.
